摘要
目的探讨血清肿瘤标志物CA125、CA724及CYFRA21-1对晚期非小细胞肺癌化疗疗效的预测价值。方法选取42例经病理证实的初治晚期非小细胞肺癌患者,予GP方案(泽菲+顺铂)一线化疗,于治疗开始前及化疗两周期后抽取患者外周静脉血,采用放射免疫法检测患者血清CA125、CA724及CYFRA21-1的浓度。结果血清CA125水平在稳定组和进展组患者化疗前后的差异有统计学意义(P<0.05);CA724在进展组患者的表达明显高于稳定组(P<0.05);稳定组和进展组及两组化疗前后均未见CYFRA21-1浓度的变化。结论晚期非小细胞肺癌患者血清CA125的变化与GP方案化疗反应有关,CA724的浓度可作为化疗疗效的预测指标。
Objective To determine the prognostic value of serum tumor marker CA125、CA724及CYFRA21-1 for GP chemotherapy in patients with advanced non-small cell lung cancer.Methods forty-two advanced non-small cell lung cancer patients without prior therapy were eligible for this study,and were treated with GP(gemcitabine+cisplain).Blood sample were obtained before the chemotherapy and after two cycles.The expression of CA125、CA724及CYFRA21-1 in serum were examined by radioimmunoassay.Results The level of CA125 decreased significantly in the stable group and increased in the progressive group(P〈0.05);The different expression of CA724 were observed in the stable group and progressive group(P〈0.05);There were no significant change of the level of CYFRA21-1 between the two groups.Conclusion The change of CA125 may be used for the prediction of clinical reaction in advanced NSCLC patients treated with GP,and the level of CA724 correlates with the clinical reaction.
出处
《临床肺科杂志》
2011年第2期232-233,共2页
Journal of Clinical Pulmonary Medicine